CN1861091A - Load type molecular iodine complementary agent, and its prepn. method and use - Google Patents
Load type molecular iodine complementary agent, and its prepn. method and use Download PDFInfo
- Publication number
- CN1861091A CN1861091A CNA2006100503186A CN200610050318A CN1861091A CN 1861091 A CN1861091 A CN 1861091A CN A2006100503186 A CNA2006100503186 A CN A2006100503186A CN 200610050318 A CN200610050318 A CN 200610050318A CN 1861091 A CN1861091 A CN 1861091A
- Authority
- CN
- China
- Prior art keywords
- iodine
- iodide
- brucite
- load type
- type molecular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 title claims abstract description 138
- 239000003795 chemical substances by application Substances 0.000 title claims description 35
- 238000000034 method Methods 0.000 title claims description 15
- 230000000295 complement effect Effects 0.000 title 1
- 239000011630 iodine Substances 0.000 claims abstract description 67
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 67
- 239000003814 drug Substances 0.000 claims abstract description 20
- 238000006243 chemical reaction Methods 0.000 claims abstract description 16
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims abstract description 16
- 241000282414 Homo sapiens Species 0.000 claims abstract description 6
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 claims abstract description 6
- 230000001590 oxidative effect Effects 0.000 claims abstract description 6
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 claims abstract description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract 8
- 229910052599 brucite Inorganic materials 0.000 claims description 61
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 33
- 239000002002 slurry Substances 0.000 claims description 30
- 239000000725 suspension Substances 0.000 claims description 30
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 20
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 230000018044 dehydration Effects 0.000 claims description 11
- 238000006297 dehydration reaction Methods 0.000 claims description 11
- 239000012065 filter cake Substances 0.000 claims description 11
- 239000004151 Calcium iodate Substances 0.000 claims description 9
- UHWJJLGTKIWIJO-UHFFFAOYSA-L calcium iodate Chemical compound [Ca+2].[O-]I(=O)=O.[O-]I(=O)=O UHWJJLGTKIWIJO-UHFFFAOYSA-L 0.000 claims description 9
- 235000019390 calcium iodate Nutrition 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical group [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims description 9
- 239000001230 potassium iodate Substances 0.000 claims description 9
- 235000006666 potassium iodate Nutrition 0.000 claims description 9
- 229940093930 potassium iodate Drugs 0.000 claims description 9
- 235000009518 sodium iodide Nutrition 0.000 claims description 9
- 238000001354 calcination Methods 0.000 claims description 8
- LHJQIRIGXXHNLA-UHFFFAOYSA-N calcium peroxide Chemical compound [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- XZXYQEHISUMZAT-UHFFFAOYSA-N 2-[(2-hydroxy-5-methylphenyl)methyl]-4-methylphenol Chemical compound CC1=CC=C(O)C(CC=2C(=CC=C(C)C=2)O)=C1 XZXYQEHISUMZAT-UHFFFAOYSA-N 0.000 claims description 7
- 229940107816 ammonium iodide Drugs 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 claims description 6
- 241001494479 Pecora Species 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 claims description 6
- 229910001641 magnesium iodide Inorganic materials 0.000 claims description 6
- 229910021645 metal ion Inorganic materials 0.000 claims description 6
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 claims description 6
- 244000144977 poultry Species 0.000 claims description 6
- 239000011697 sodium iodate Substances 0.000 claims description 6
- 235000015281 sodium iodate Nutrition 0.000 claims description 6
- 229940032753 sodium iodate Drugs 0.000 claims description 6
- 229910001640 calcium iodide Inorganic materials 0.000 claims description 5
- 229940046413 calcium iodide Drugs 0.000 claims description 5
- 239000007800 oxidant agent Substances 0.000 claims description 5
- ACAYDTMSDROWHW-UHFFFAOYSA-M potassium;iodic acid;iodate Chemical compound [K+].OI(=O)=O.[O-]I(=O)=O ACAYDTMSDROWHW-UHFFFAOYSA-M 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000004343 Calcium peroxide Substances 0.000 claims description 4
- 235000019402 calcium peroxide Nutrition 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 229960004839 potassium iodide Drugs 0.000 claims description 4
- 229940083599 sodium iodide Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019730 animal feed additive Nutrition 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229940045872 sodium percarbonate Drugs 0.000 claims description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 claims description 2
- 239000012279 sodium borohydride Substances 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 14
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 abstract description 3
- 229960001545 hydrotalcite Drugs 0.000 abstract 2
- 229910001701 hydrotalcite Inorganic materials 0.000 abstract 2
- 241000272496 Galliformes Species 0.000 abstract 1
- 239000004459 forage Substances 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 10
- -1 Nucleoside Monophosphates Chemical class 0.000 description 9
- 206010067997 Iodine deficiency Diseases 0.000 description 8
- 235000006479 iodine deficiency Nutrition 0.000 description 8
- 230000002687 intercalation Effects 0.000 description 7
- 238000009830 intercalation Methods 0.000 description 7
- 239000011229 interlayer Substances 0.000 description 6
- 210000001685 thyroid gland Anatomy 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 4
- 208000011803 breast fibrocystic disease Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 241000238557 Decapoda Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010058667 Oral toxicity Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 231100000418 oral toxicity Toxicity 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- DHZVWQPHNWDCFS-UHFFFAOYSA-N 2-hydroxy-3,5-diiodobenzoic acid Chemical compound OC(=O)C1=CC(I)=CC(I)=C1O DHZVWQPHNWDCFS-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010001767 Alopecia universalis Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 229910001051 Magnalium Inorganic materials 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 241000543821 Oestrus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000736919 Pelodiscus sinensis Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- UOZDOLIXBYLRAC-UHFFFAOYSA-L [2-hydroxy-3-(trimethylazaniumyl)propyl]-trimethylazanium;diiodide Chemical compound [I-].[I-].C[N+](C)(C)CC(O)C[N+](C)(C)C UOZDOLIXBYLRAC-UHFFFAOYSA-L 0.000 description 1
- SHOKWSLXDAIZPP-UHFFFAOYSA-N [4-(4-iodooxy-2-methyl-5-propan-2-ylphenyl)-5-methyl-2-propan-2-ylphenyl] hypoiodite Chemical compound C1=C(OI)C(C(C)C)=CC(C=2C(=CC(OI)=C(C(C)C)C=2)C)=C1C SHOKWSLXDAIZPP-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000032775 alopecia universalis congenita Diseases 0.000 description 1
- UKFWSNCTAHXBQN-UHFFFAOYSA-N ammonium iodide Chemical class [NH4+].[I-] UKFWSNCTAHXBQN-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000011011 black crystal Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000006253 efflorescence Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MPNNOLHYOHFJKL-UHFFFAOYSA-N peroxyphosphoric acid Chemical compound OOP(O)(O)=O MPNNOLHYOHFJKL-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000967 thyroidotoxicity Toxicity 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An iodine supplement used for the forage of animals and fowls and human health-care food or medicine is a hydrotalcite carried molecular iodine. It is prepared through providing hydrotalcite as micro reactor and reducing or oxidizing reaction to reduce iodic acid (or iodate) or oxidize iodide to obtain molecular iodine.
Description
Technical field
The present invention relates to a kind of iodine-replenishing agent and preparation method and purposes of load type molecular iodine, is a kind of iodine-replenishing agent and preparation method and purposes of brucite load molecular iodine specifically.
Background technology
One, the application of iodine on herding is produced
Iodine is requisite composition in the thyroid.Its biochemical function mainly is to show by thyroxin, and is very extensive to the biological action of body, mainly contains: (1) is regulated metabolism and is kept thermal balance in the body.(2) influence animal growth: the unify growth of digestive system has regulating and controlling effect to iodine to central nervous system, skeletal system, cardiovascular system, can promote histo-differentiation and growth, thereby promote the growth promoter of young animal.The young animal iodine deficiency can show as that growth promoter is obstructed, vitality descends, cause " cretinism ".(3) influence the animal reproduction performance: iodine deficiency can cause animal reproduction disorder, oestruses undesired or oestrus to be suppressed even sterile.Serious iodine deficiency also can influence the offspring, makes offspring's growth retardation, hypoplasia.The buck iodine deficiency can cause libido to descend, and semen quality is inferior.The jenny iodine deficiency can cause that conception rate descends, miscarriage, produce weak tire and puerperal placenta retention etc.Plant the chicken iodine deficiency and can cause incubation rate reduction, yolk sac malabsorption, brooding time prolongation etc.(4) influence the coat condition of animal: iodine deficiency can influence the fur normal growth of animal, and cause by fur skin drying, filth, poor growth, fall overly floating-weak pulse to alopecia universalis, pachyderma, hair, feather tarnish, and the whole body is by wool fibreization etc.(5) the animal iodine deficiency also can cause the content of iodine in its product to descend, and enriches the iodine and can produce rich iodine product, as iodine-enriched egg or rich iodine milk.
According to " allow use feed additive kind catalogue " of the up-to-date promulgation of China, can be used for trace compound that poultry enrich the iodine has 3 kinds of potassium iodide, potassium iodate and calcium iodate.Other chemical compound that contains iodine also has sodium iodide, ethylenediamine dihydroiodide, Hydro-Giene (Water Science)., 3,5-diiodosalicylic acid, thymiodol etc.Potassium iodide, sodium iodide poor stability easily by the effect of other the micro-first rope in airborne oxygen and the feedstuff and oxidized its biological activity of causing descends, even completely lose.In addition, when potassium iodide and other micro-first rope (as copper sulfate) compatibility, the rope A that supports one's family there is the ashamed usefulness of intensive collaborative destruction.Potassium iodate, calcium iodate are more stable, and its biological value is similar to potassium iodide, but stronger oxidant is bigger to the destruction of vitamin, and be stronger to the gastrointestinal irritation of animal.In addition, for culture fishery, aquatic feeds must drop into water body, fish and shrimp just can be ingested, in case and feedstuff entry, just be subjected to the influence of various factors (pH, temperature, osmotic pressure, wave current impact, chemical reaction etc.), produced various reactions, as dissolving, swelling, fracture, efflorescence, peel off etc.Chen Siqing etc. (1995) have studied that the prawn mixed feed is dipped in the wastage of each nutritional labeling in the water and to Effects of water environment, the molten mistake of finding mineral is very rapidly and completely, only with the percentage composition rate of descent, in the time of 5 minutes, descended 16.4～40.8%, in the time of 90 minutes, descended 69.4～76.7%, reach 84.4～93.9% in the time of 120 minutes, if calculate the weightless loss that causes, then molten mistake is totally in the time of 120 minutes for mineral.After inorganic microelement such as potassium iodide, the potassium iodate entry, be easy to molten mistake and be dissolved in the water, cause the waste of propiodal and the pollution of water environment.
Two, molecular iodine the mankind enrich the iodine and disease treatment on application
Iodine comprises that organic bonded iodine, inorganic iodine and molecular iodine (are I
2) can be used for treating human diseases.Prior art confirms that molecular iodine is effective therapeutic agent of multiple disease.An important parameter of iodine medicine is its therapeutic index, and molecular iodine is high more with the ratio of total iodine, and the therapeutic index of iodine composition is high more.For example, Eskin etc. (" analysis on trace biology " (Biological TraceElement Research), 49 volumes, 9-18 page or leaf, 1995) confirm, molecular iodine " obviously effective than iodide in reducing cyclomastopathy and leaf week fibrosis ".The document points out that also the oral toxicity of iodide is greater than molecular iodine.United States Patent (USP) 4,816,255; 5,171,582; 5,250,304 and 5,389,385 disclose and have been used for the human oral administration to treat " molecular iodine " (I of various human diseasess
2) compositions of Yu Shuizhong.United States Patent (USP) 5,589,198 disclose use molecular iodine or " iodine metal " and pharmaceutically suitable carrier beneficial effect in the treatment fibrocystic breast syndrome.Chinese patent 98809764.8 relates to that method that in mammiferous stomach original position produces molecular iodine for example is used for the treatment of fibrocystic breast syndrome and other needs are chronic or the disease of acute dose drug treatment iodine, wherein, the proportion control of the molecular iodine of the therapeutic iodine of institute's administration and total iodine is between 0.8～1.0.
Worry it is the probability of toxic reaction about the maximum of administration iodine medicine.Iodism can cause a series of symptom.Described symptom comprises that oral cavity and throat are scorching hot; Tooth and gingiva pain; Salivation increases; Rhinitis, respiratory tract irritate; Cough; Headache; Body of gland increases; Pharynx, larynx and tonsil inflammation; Skin injury; Stomach irritates; Diarrhoea; Fever; Anorexia and depression; May take place serious, be fatal eruption (iododerma) sometimes.
In the early 1990s the phase, the relative oral toxicity of molecular iodine and iodide has been carried out scientific research.Sherer etc. (1991) report, can increase the thyroid weight of rat to the inferior chronic administration iodide of male rat with the iodide concentration of 10mg/kg; Even molecular iodine does not influence thyroid weight under the concentration of 100mg/kg yet; Up to the increase that animal is just recorded the thyroxin steady-state level during administration every day molecular iodine repeatedly with the dosage of 10mg/kg body weight.From these experiments as can be seen, iodide can produce the influence to mammal thyroid weight suitable with the molecular iodine effect under the concentration than low 10 times of molecular iodine.That is to say that during the oral administration iodine composition, need Duo 10 times molecular iodine than iodide could influence the thyroid function of animal.Molecular iodine and iodide compare thyroid toxicity to be reduced this fact and has very important enlightenment meaning for the design of oral iodine medicine.These studies show that when all other factors homogeneous phases whiles, molecular iodine is preferred oral iodine medicine form.This is particularly correct for the disease that needs the described iodine medicine of long term administration.Therefore, prior art has shown that all iodine all should be molecular iodine in preferred oral iodine medicine.
Once the inorganic iodine compositions that was used as oral therapeutics comprises sodium iodide or potassium iodide; Iodine tincture or Lugol's Solution; Can generate the organic iodide of iodide ion.The Aquo-composition of these materials itself contains the molecular iodine of the ratio of low-down and/or unpredictable and total iodine.In mole, the contained molecular iodine of these compositionss is usually less than other iodine form.For example, Lugol's Solution contains total iodine of the 129000ppm that has an appointment, but the molecular iodine of 170ppm is only arranged, and its ratio is 0.0013.
Commercially available I
2Be blue-black crystal, have very bright metallic luster.The existing main difficulty of suitable for oral administration compositions of preparation molecular iodine is relevant with the basic physicochemical properties of this element.The I of all solids form
2All be easy to distillation and form the purple steam.I
2The inherent characteristic that is easy to distil has caused the unstability of itself, and this has just limited its application as active component in pharmaceutical preparation.And, I
2Be unsettled in water, in aqueous system, molecular iodine can and experience the series reaction shown in the following equation 1-3 by the water hydration:
For clinical practice, the solution to this restriction was to use immediately then at the aqueous solution that faces with preceding preparation iodine in the past.Solid I
2Dissolving in water is very slow.Dissolved solid I
2The required I that can cause some new formation for a long time
2Owing to taking place, the reaction with water shown in the above equation 1 loses.
As mentioned above, I
2Can at room temperature distil and react with water.These two kinds of character cause being very difficult to prepare molecular iodine; Especially be difficult to prepare the compositions that wherein most of iodine exists with the molecular iodine form.
Three, brucite
Brucite (Hydrotalcites, or Layered Double Hydroxides, LDHs) be the anionic inorganic functional material, possess the Modulatory character of laminate chemical composition, leafing subcategory and quantity, crystallite dimension and distribution thereof on the structure, have purposes widely at aspects such as catalysis, ion exchange, absorption, chemical industry.In recent years, along with the development of cross discipline research field, brucite has had new application at aspects such as biological medicines, and brucite is realized commercialization rapidly as the specific drug of treatment gastropathy in Europe.Performance that the intercalation that utilizes brucite to have is assembled and good biocompatibility, its transport vehicle as the bio-pharmaceutical molecule had very high using value, brucite is considered to the spacetabs type carrier of a class formation and mechanism of action novelty, more and more is subjected to the extensive concern of researcher.
Document 1:Choy, J.K., Kwak, S.Y., Jeong, Y.J., Park, J.S.2000.Inorganic layerd doublehydroxides as nonviral vectors.Angew.Chem.39, people such as 4041～4045.Choy are successfully with biomolecule nucleotide (Nucleoside Monophosphates) and DNA (deoxyribonucleic acid) (Deoxyribonucleic Acid, DNA) method with ion exchange is inserted into the LDHs interlayer, forms bio-LDH layer molecule composite.Brucite is used as the transport vehicle of biomolecule.
Document 2:Khan AI, Lei L, Norquist AJ, O ' Hare D.Intercalation and controlled release ofpharmaceutically active compounds from a layered double hydroxide.Chem Commun (Camb), 2001,21:2342-2343. has prepared anti-inflammatory agent intercalated houghites such as diclofenac, ibuprofen and naproxen.
Document 3:Ambrogi V, Fardella G, Grandolini G, Perioli L.Intercalation compounds ofhydrotalcite-like anionic clays with antiinflammatory agents--I.Intercalation and in vitro release ofibuprofen.Int J Pharm., 2001,220:23-32. brucite is used as the transport vehicle of medicament slow release, carried out the intercalation of ibuprofen in brucite, release performance to the intercalation product studies show that, under the condition of pH neutral, the rate of release of medicine becomes slowly, has reached the purpose that delays drug release.
Brucite will destroy its layer structure 450 ℃～550 ℃ following calcinings, obtain bimetallic oxide.Bimetallic oxide can come the restoration and reconstruction hydrotalcite structure by anion and the hydrone in the absorption environment, and because of having bigger specific surface area and pore volume, acceptant object.Bimetallic oxide after the roasting has bigger specific surface area than its predecessor, and has structure " memory " effect, promptly reuptakes anion and make it recover original layer structure in water environment.
The nano pore structure of brucite can be used as " microreactor ".Adopt brucite as template, in its confinement space, can impel product in mould, to grow or grow, realize that the expection of product structure is controlled around mould.Chinese patent 200310103598.9 is introduced the LDHs interlayer with the interlayer of the LDHs reaction compartment as monomer polymerization with monomer, obtains interlayer and contains monomeric LDHs; Make this monomer at the interlayer polymerization reaction take place again, obtain the LDHs that interlayer contains polymer.Owing to will be subjected to the restriction of template at the molecular chain structure of the confinement space of template interpolymer etc., therefore can prepare the polymer of nano-scale, laminated structure.
Summary of the invention
The iodine-replenishing agent and preparation method and the purposes that the purpose of this invention is to provide a kind of load type molecular iodine are a kind of iodine-replenishing agent and preparation method and purposes of brucite load molecular iodine specifically.
The iodine-replenishing agent of load type molecular iodine is a kind of brucite load molecular iodine, and by weight percentage, the content of iodine in brucite is 0.5～5%.
The preparation method of the iodine-replenishing agent of load type molecular iodine may further comprise the steps:
1) brucite or bimetallic oxide are ground to greater than 400 orders, add water and stir, make concentration and be 1%～10% suspension slurry:
2) with amount of iodine be the iodate or the iodide of brucite or bimetallic oxide weight 0.5～5%, be pre-configured to the aqueous solution of 0.01～1.0mol/L, slowly add in the suspension slurry of step 1) in stirring down, add molar ratio again and be the iodine Reducing agent or the oxidant of 1～5 times in iodate or iodide, regulate pH=3.0～6.0, room temperature reaction 1～10 hour;
3) the centrifugal or filtering means dehydration of suspension slurry step 2);
4) filter cake of step 3) gained is dried, is crushed to greater than 300 orders, obtain the iodine-replenishing agent of load type molecular iodine.
The brucite that uses among the present invention can be the commercial goods, also can be according to prior art for preparing, and its technology of preparing is well-known.The brucite chemical structure of general formula is: [M
2+ 1-xM
3+ x(OH)
2]
X+[A
N- X/nMH
2O], wherein, bivalent metal ion M
2+Be Mg
2+, Zn
2+, Fe
2+, Mn
2+, Co
2+, Ni
2+, Cu
2+, Ca
2+In any, trivalent metal ion M
3+Be Al
3+, Fe
3+, Cr
3+, Co
3+, Ti
3+In any; A
N-Be CO
3 2-, Cl
-, NO
3 -, SO
4 2-In any; X=0.5～0.17; M
2+/ M
3+=1～5.The bimetallic oxide that uses in the invention is for forming above-mentioned brucite at 450～550 ℃ of temperature lower calcinations.
Iodic acid (salt) is iodic acid, potassium iodate, potassium hydrogen diiodate, sodium iodate or calcium iodate.Said iodide are sodium iodide, potassium iodide, ammonium iodide, calcium iodide or magnesium iodide.Said iodine Reducing agent is sodium iodide, potassium iodide, ammonium iodide, calcium iodide, magnesium iodide, vitamin C, mercaptoethanol, lactose, sodium thiosulfate, potassium borohydride or sodium borohydride.
Oxidant is iodic acid, potassium iodate, potassium hydrogen diiodate, sodium iodate, calcium iodate or hydrogen peroxide source.
Said hydrogen peroxide source is one or more of hydrogen peroxide, calper calcium peroxide, SODIUM PERCARBONATE or urea peroxide.
The serosity dewatering process of preparation method, but treatment in accordance with local conditions are selected for use centrifugal or method such as filtration is dewatered.The filter cake of dehydration back gained can use conventional drying plant drying.The iodine-replenishing agent of the load type molecular iodine after the oven dry is block, can select for use conventional disintegrating apparatus to be crushed to granularity greater than 300 orders.
The iodine-replenishing agent of load type molecular iodine is as cattle, sheep, poultry, the aquatic animal feed additive that enriches the iodine.The iodine-replenishing agent of load type molecular iodine is used to prepare the health product or the medicine of treatment fibrocystic breast syndrome, breast carcinoma, premenstrual tension syndrome, endometriosis and gastric ulcer.
Advantage of the present invention is:
(1) utilize the intercalation assembling performance of brucite and bimetallic oxide to carry iodine by the character of layer structure reconstruction adsorpting anion, and utilize brucite as the synthetic load type molecular iodine of microreactor, solved the molecular iodine stability problem preferably, implementation method is easy, suitability for industrialized production.
(2) brucite has good biocompatibility and gastrointestinal tract mucous affinity, and characteristics such as high surface and huge specific surface area make it that the molecular iodine of institute's load is had the control slow releasing function, thereby improved the absorption rate of molecular iodine greatly.
(3) the prepared load type molecular iodine of the present invention has low toxicity, characteristics of high efficiency, can be used as feed additive and be applied to enriching the iodine of cattle, sheep, poultry, aquatic animal etc., can be used for also preparing that the mankind enrich the iodine and treat the health product or the medicine of human diseases by the iodine of drug treatment.
(4) load type molecular iodine is easy to mix with feedstuff, forms homodisperse system, and is easy to use.
The specific embodiment
The present invention is further described in conjunction with following example.
Embodiment 1
Preparation: according to " is oral vanadium replenishing agent and the preparation and the using method of carrier with the bimetallic oxide " Ye Ying, Feng Lujia, Zheng Libo, Shen Zhongyue, Han Jie, Chen Zhifei, Li Shanshan. national inventing patent Granted publication CN 1187091C) method prepare brucite.
1) brucite that obtains in the preliminary step is ground to 400 orders, adds water and stir, make concentration and be 1% suspension slurry:
2) with amount of iodine be the potassium iodate of brucite weight 0.5%, be pre-configured to the aqueous solution of 0.01mol/L, slowly add in the suspension slurry of step 1) in stirring down, adding molar ratio again is the potassium iodide of 5 times of potassium iodate, regulate pH=6.0, room temperature reaction 10 hours;
3) suspension slurry centrifuge dehydration step 2);
4) filter cake of step 3) gained is dried, is crushed to 500 orders, obtain the iodine-replenishing agent of load type molecular iodine, by weight percentage, iodine content in brucite is 0.5%.
Embodiment 2
The preparation: according to " a kind of method for preparing bimetallic oxide and brucite " (Ye Ying, Li Shanshan, Chen Zhifei, Zheng Libo, Huang Xia, Wu Daidai, Han Jie, Zhang Weirui. national inventing patent Granted publication CN 1222467C) method prepare brucite.
1) brucite that obtains in the preliminary step is ground to 500 orders, adds water and stir, make concentration and be 5% suspension slurry:
2) with amount of iodine be the sodium iodate of brucite weight 1.5%, be pre-configured to the aqueous solution of 0.05mol/L, slowly add in the suspension slurry of step 1) in stirring down, adding molar ratio again is the sodium thiosulfate of 1.5 times of sodium iodate, regulate pH=5.0, room temperature reaction 5 hours;
3) suspension slurry filtering means dehydration step 2);
4) filter cake of step 3) gained is dried, is crushed to 300 orders, obtain the iodine-replenishing agent of load type molecular iodine, by weight percentage, iodine content in brucite is 1.5%.
Embodiment 3
1) with commercially available brucite at 450 ℃ of temperature lower calcinations, make bimetallic oxide, be ground to 500 orders again, add water and stir, make concentration and be 10% suspension slurry:
2) with amount of iodine be the potassium hydrogen diiodate of brucite weight 5%, be pre-configured to the aqueous solution of 1.0mol/L, slowly add in the suspension slurry of step 1) in stirring down, adding molar ratio again is the potassium borohydride of 2 times of potassium hydrogen diiodates, regulate pH=6.0, room temperature reaction 8 hours;
3) suspension slurry centrifuge dehydration step 2);
4) filter cake of step 3) gained is dried, is crushed to 400 orders, obtain the iodine-replenishing agent of load type molecular iodine, by weight percentage, iodine content in brucite is 5%.
Embodiment 4
1) commercially available brucite is ground to 600 orders, adds water and stir, make concentration and be 10% suspension slurry:
2) with amount of iodine be the calcium iodide of brucite weight 1.5%, be pre-configured to the aqueous solution of 0.05mol/L, slowly add in the suspension slurry of step 1) in stirring down, adding molar ratio again is the hydrogen peroxide of 2 times of calcium iodides, regulate pH=3.0, room temperature reaction 1 hour;
3) suspension slurry filtering means dehydration step 2);
4) filter cake of step 3) gained is dried, is crushed to 400 orders, obtain the iodine-replenishing agent of load type molecular iodine, by weight percentage, iodine content in brucite is 1.5%.
Embodiment 5
1) with commercially available brucite at 550 ℃ of temperature lower calcinations, make bimetallic oxide, be ground to 500 orders again, add water and stir, make concentration and be 10% suspension slurry:
2) with amount of iodine be the calcium iodate of brucite weight 5%; Be pre-configured to the aqueous solution of 0.01mol/L, slowly add in the suspension slurry of step 1) in stirring down, adding molar ratio again is the lactose of 2 times of calcium iodate, regulates pH=3.5, room temperature reaction 7 hours;
3) suspension slurry filtering means dehydration step 2);
4) filter cake of step 3) gained is dried, is crushed to 500 orders, obtain the iodine-replenishing agent of load type molecular iodine, by weight percentage, iodine content in brucite is 5%.
Embodiment 6
Preparation: according to " magnalium type brucite hydro-thermal synthetic " (Xie Hui rectifys the celebrating pool, section snow. applied chemistry, 2001, method 18:70-72) prepares brucite.
1) with the brucite that obtains in the preliminary step at 550 ℃ of temperature lower calcinations, make bimetallic oxide, be ground to 600 orders again, add water and stir, make concentration and be 5% suspension slurry:
2) be the sodium iodide of brucite weight 3% with amount of iodine, be pre-configured to the aqueous solution of 0.5mol/L, slowly add down in the suspension slurry of step 1), add again and the equimolar calcium iodate of sodium iodide, regulate pH=4.5, room temperature reaction 5 hours in stirring;
3) suspension slurry centrifuge dehydration step 2);
4) filter cake of step 3) gained is dried, is crushed to 300 orders, obtain the iodine-replenishing agent of load type molecular iodine, by weight percentage, iodine content in brucite is 3%.
Embodiment 7
Preparation: according to " binary metal houghite synthetic and as the Study on adsorption properties of presoma " (Guo Zhiqiang, Ni Zheming, Yu Weihua to NOx, Wang Ligeng, Ge Zhonghua. the Materials Science and Engineering journal, 2004,22 (6): method 878-880) prepares brucite.
1) with the brucite that obtains in the preliminary step at 500 ℃ of temperature lower calcinations, make bimetallic oxide, be ground to 500 orders again, add water and stir, make concentration and be 3% suspension slurry:
2) with amount of iodine be the magnesium iodide of brucite weight 3.5%, be pre-configured to the aqueous solution of 0.1mol/L, under stirring, slowly add in the suspension slurry of step 1), again the hydrogen peroxide and the calper calcium peroxide of molal quantitys such as adding and magnesium iodide, regulate pH=3.0, room temperature reaction 6 hours;
3) suspension slurry filtering means dehydration step 2);
4) filter cake of step 3) gained is dried, is crushed to 300 orders, obtain the iodine-replenishing agent of load type molecular iodine, by weight percentage, iodine content in brucite is 3.5%.
Embodiment 8
1) with commercially available brucite at 480 ℃ of temperature lower calcinations, make bimetallic oxide, be ground to 500 orders again, add water and stir, make concentration and be 10% suspension slurry:
2) with amount of iodine be the ammonium iodide of brucite weight 3%, be pre-configured to the aqueous solution of 0.25mol/L, slowly add in the suspension slurry of step 1) in stirring down, calper calcium peroxide, the molar ratio that adds molar ratio again and be 0.5 times of ammonium iodide is that the SODIUM PERCARBONATE and the molar ratio of 1.5 times of ammonium iodides is the peroxophosphoric acid sodium of 0.5 times of ammonium iodide, regulate pH=6.0, room temperature reaction 5 hours;
3) suspension slurry centrifuge dehydration step 2);
4) filter cake of step 3) gained is dried, is crushed to 500 orders, obtain the iodine-replenishing agent of load type molecular iodine, by weight percentage, iodine content in brucite is 3%.
The iodine-replenishing agent of load type molecular iodine is as cattle, sheep, poultry, the aquatic animal feed additive that enriches the iodine.Using method is: with the iodine-replenishing agent of pulverous load type molecular iodine, admix (in iodine) in cattle, sheep, poultry, the aquatic animal feed by following additive capacity: cattle 0.1～0.5mg/kg, sheep 0.1～0.4mg/kg, pig 0.1～0.5mg/kg, chicken 0.1～1mg/kg, duck 0.1～0.5mg/kg, fish 0.1～0.5mg/kg, Trionyx sinensis Wiegmann 0.2～1.5mg/kg, shrimp 0.2～1.5mg/kg.
The iodine-replenishing agent of load type molecular iodine is used for the treatment of fibrocystic breast syndrome, breast carcinoma, premenstrual tension syndrome, endometriosis and gastric ulcer.Using method is: dosage every day that is used for the treatment of the required molecular iodine of mammary gland dysplasia: the women for body weight 60kg is 0.5～15mg/ days, and the amount ranges of preferred iodine is 2.0～7.5mg/ days.Be used to prevent dosage every day of the required molecular iodine of mammary gland dysplasia: the women for body weight 60kg is 0.125～1.5mg/ days, and the amount ranges of preferred iodine is 0.225～1.25mg/ days.Dosage every day that is used for the molecular iodine of acute administration can be 15～125mg/ days, and the amount ranges of preferred iodine is 20～55mg/ days.
Claims (10)
1. the iodine-replenishing agent of a load type molecular iodine is characterized in that, it is a kind of brucite load molecular iodine, and by weight percentage, the content of iodine in brucite is 0.5～5%.
2. the iodine-replenishing agent of a kind of load type molecular iodine according to claim 1 is characterized in that, said brucite chemical structure of general formula is: [M
2+ 1-xM
3+ x(OH)
2]
X+[A
N- X/nMH
2O], wherein, bivalent metal ion M
2+Be Mg
2+, Zn
2+, Fe
2+, Mn
2+, Co
2+, Ni
2+, Cu
2+, Ca
2+In any, trivalent metal ion M
3+Be Al
3+, Fe
3+, Cr
3+, Co
3+, Ti
3+In any; A
N-Be CO
3 2-, Cl
-, NO
3 -, SO
4 2-In any; X=0.5～0.17; M
2+/ M
3+=1～5.
3. the preparation method of the iodine-replenishing agent of a load type molecular iodine as claimed in claim 1 is characterized in that the step of method is as follows:
1) brucite or bimetallic oxide are ground to greater than 400 orders, add water and stir, make concentration and be 1%～10% suspension slurry;
2) with amount of iodine be the iodate or the iodide of brucite or bimetallic oxide weight 0.5～5%, be pre-configured to the aqueous solution of 0.01～1.0mol/L, slowly add in the suspension slurry of step 1) in stirring down, add molar ratio again and be the iodine Reducing agent or the oxidant of 1～5 times in iodate or iodide, regulate pH=3.0～6.0, room temperature reaction 1～10 hour;
3) the centrifugal or filtering means dehydration of suspension slurry step 2);
4) filter cake of step 3) gained is dried, is crushed to greater than 300 orders, obtain the iodine-replenishing agent of load type molecular iodine.
4. the preparation method of the iodine-replenishing agent of a kind of load type molecular iodine according to claim 3 is characterized in that, said bimetallic oxide is for to form brucite at 450～550 ℃ of temperature lower calcinations.
5. the preparation method of the iodine-replenishing agent of a kind of load type molecular iodine according to claim 3 is characterized in that, said brucite chemical structure of general formula is: [M
2+ 1-xM
3+ x(OH)
2 X+[A
N- X/nMH
2O], wherein, bivalent metal ion M
2+Be Mg
2+, Zn
2+, Fe
2+, Mn
2+, Co
2+, Ni
2+, Cu
2+, Ca
2+In any, trivalent metal ion M
3+Be Al
3+, Fe
3+, Cr
3+, Co
3+, Ti
3+In any; A
N-Be CO
3 2-, Cl
-, NO
3 -, SO
4 2-In any; X=0.5～0.17; M
2+/ M
3+=1～5.
6. the preparation method of the iodine-replenishing agent of a kind of load type molecular iodine according to claim 3, it is characterized in that, said iodate is potassium iodate, potassium hydrogen diiodate, sodium iodate or calcium iodate, and said iodide are sodium iodide, potassium iodide, ammonium iodide, calcium iodide or magnesium iodide.
7. the preparation method of the iodine-replenishing agent of a kind of load type molecular iodine according to claim 3, it is characterized in that, said iodine Reducing agent is sodium iodide, potassium iodide, ammonium iodide, calcium iodide, magnesium iodide, vitamin C, mercaptoethanol, lactose, sodium thiosulfate, potassium borohydride or sodium borohydride, and said oxidant is iodic acid, potassium iodate, potassium hydrogen diiodate, sodium iodate, calcium iodate or hydrogen peroxide source.
8. the preparation method of the iodine-replenishing agent of a kind of load type molecular iodine according to claim 7 is characterized in that, said hydrogen peroxide source is one or more of hydrogen peroxide, calper calcium peroxide, SODIUM PERCARBONATE or urea peroxide.
9. the purposes of the iodine-replenishing agent of a load type molecular iodine as claimed in claim 1 is characterized in that it is used as cattle, sheep, poultry, the aquatic animal feed additive that enriches the iodine.
10. the purposes of the iodine-replenishing agent of a load type molecular iodine as claimed in claim 1 is characterized in that being used to preparing that the mankind enrich the iodine and treat the health product or the medicine of human diseases by the iodine of drug treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100503186A CN100364547C (en) | 2006-04-12 | 2006-04-12 | Load type molecular iodine complementary agent, and its prepn. method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100503186A CN100364547C (en) | 2006-04-12 | 2006-04-12 | Load type molecular iodine complementary agent, and its prepn. method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1861091A true CN1861091A (en) | 2006-11-15 |
| CN100364547C CN100364547C (en) | 2008-01-30 |
Family
ID=37388677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100503186A Expired - Fee Related CN100364547C (en) | 2006-04-12 | 2006-04-12 | Load type molecular iodine complementary agent, and its prepn. method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100364547C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011509914A (en) * | 2008-01-25 | 2011-03-31 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ | Process for producing zero waste liquid discharge of stable synthetic hydrotalcite ion-exchanged with iodate ion |
| CN102167390A (en) * | 2011-01-31 | 2011-08-31 | 浙江工业大学 | Zn-Al binary hydrotalcite and application thereof as sustained-release iodine material |
| CN103467306A (en) * | 2013-08-21 | 2013-12-25 | 浙江工业大学 | Synthetic method of iodo-aniline derivatives |
| CN107089919A (en) * | 2017-05-23 | 2017-08-25 | 浙江工业大学 | Method for synthesizing monobromoanilide compound |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187091C (en) * | 2002-09-24 | 2005-02-02 | 浙江大学 | Oral vanadium replenishing agent with bimetallic oxide as carrier and its prepn and usage |
-
2006
- 2006-04-12 CN CNB2006100503186A patent/CN100364547C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011509914A (en) * | 2008-01-25 | 2011-03-31 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ | Process for producing zero waste liquid discharge of stable synthetic hydrotalcite ion-exchanged with iodate ion |
| CN102167390A (en) * | 2011-01-31 | 2011-08-31 | 浙江工业大学 | Zn-Al binary hydrotalcite and application thereof as sustained-release iodine material |
| CN103467306A (en) * | 2013-08-21 | 2013-12-25 | 浙江工业大学 | Synthetic method of iodo-aniline derivatives |
| CN103467306B (en) * | 2013-08-21 | 2015-04-22 | 浙江工业大学 | Synthetic method of iodo-aniline derivatives |
| CN107089919A (en) * | 2017-05-23 | 2017-08-25 | 浙江工业大学 | Method for synthesizing monobromoanilide compound |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100364547C (en) | 2008-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005080489A1 (en) | A solution of metal-polymer chelate(s) and applications thereof | |
| CN100364547C (en) | Load type molecular iodine complementary agent, and its prepn. method and use | |
| CN1857304A (en) | Iodine replenisher with control released iodine and its preparing method and use | |
| CN1861095A (en) | Load type super-fine copper-powder copper-complementary agent, its prepn. method and use | |
| EP3056093A3 (en) | Gel based livestock feed, method of manufacture and use | |
| CN1861093A (en) | Load type super-fine iron powder iron-complementary agent, its prepn. method and use | |
| CN100364551C (en) | Load type super-fine zinc powder zinc-complementary agent, its prepn. method and use | |
| PT1647542T (en) | Method for the production of metal carboxylates-aminoates and their use as growth promoters in animal feed | |
| CN1688511A (en) | Rare earth metal compounds, methods of making, and methods of using the same | |
| CN102951690A (en) | Oxygen supply scavenging agent for aquatic product culture | |
| CN100506068C (en) | Sustained-releasing sulfur supplementing agent, its preparation method and uses | |
| CN100506069C (en) | Molybdenium suplementing agent having controlled slow-release type molybdenium, preparation method and use thereof | |
| CN1706499A (en) | Zine replenisher with palygorskite or mentmorillonite carrier and its prepn and usage | |
| CN1187091C (en) | Oral vanadium replenishing agent with bimetallic oxide as carrier and its prepn and usage | |
| CN1321646C (en) | Oral zinc reinforcing agent using hydrotalcite as carrier, its preparation and using method thereof | |
| CN100475053C (en) | Sulfur-supported feedstuff addictive and preparation method thereof | |
| CN1186989C (en) | Chromium element feed additive using montmorillonite as carrier, its preparation method and application | |
| CN1823613A (en) | Controlled slow release type rare-earth feed additive and its preparation and use method | |
| CN100371312C (en) | Controlled release type butyric acid, its preparation method and use | |
| CN1857308A (en) | Zinc replenisher with control released zinc and its preparing method and use | |
| CN1826946A (en) | Superfine chromium-supported chromium-replenishing feedstuff addictive, its preparation and application method | |
| JP6337200B2 (en) | Copper metal micronutrient supplements | |
| CN100569092C (en) | The benefit phosphorus agent of controlled release type phosphorus and preparation method and purposes | |
| WO2005080490A1 (en) | A solution of metal-polymer chelate(s) and applications thereof | |
| CN1884261A (en) | Hydantion method compolete preparation of chromium selenomethionine compounds (III) and its uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080130 Termination date: 20120412 |